TOI · The Oncology Institute, Inc.

Current Thesis

Starling Oncology’s delegated-care expansion supports a profitability re-rating if the new contracts launch in Q4 2026 and full-year adjusted earnings meet the company’s $2 million floor; a weekly close below $5.13 invalidates the market thesis. Delegated capitation means receiving fixed payments to manage patients’ oncology care, including responsibility for treatment costs. The September 2026 investor presentation retains FY2026 revenue guidance of $650–670 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $2–7 million. September investor presentation.

The September 8 conference resolved the prior note’s missing dollar forecast: CFO Rob Carter explicitly described $300 million of 2027 capitated revenue and said most came from announced contracts. That is management’s forecast, not measured revenue; subsequent guidance below that amount would contradict it. September 8 conference transcript.

The narrative is maturing — the September presentation retains the financial framework raised on August 6, while execution remains ahead of the reported results. This is an inference about the story’s development, not evidence of expanding market participation. September investor presentation.

Bullish and bearish views on The Oncology Institute, Inc.

The model's bull view on The Oncology Institute, Inc. (TOI), in brief: Profitability has a reported foothold. The August 6 Q2 FY2026 earnings release reported adjusted EBITDA of $0.2 million, compared with a $4.1 million loss a year earlier, and gross profit of $27.2 million. Those results establish improvement, although they do not establish… The bear view: Adjusted profit remains a narrow cushion. Both cases follow in full.

Bull Case

• Profitability has a reported foothold. The August 6 Q2 FY2026 earnings release reported adjusted EBITDA of $0.2 million, compared with a $4.1 million loss a year earlier, and gross profit of $27.2 million. Those results establish improvement, although they do not establish durable profitability.
• Contracts have quantified revenue potential. Management’s August 6 Q2 call attributed approximately 80,000 additional covered lives and approximately $50 million of annualized capitated revenue to Nevada and Oregon. These are announced contract economics; launch delays or lower realized revenue would undermine the expansion case.
• Cash generation accompanied the improvement. The August 6 release reported $9.5 million of year-to-date free cash flow against FY2026 guidance of $5–15 million. This supports the financing case only while subsequent disclosures preserve positive cash generation.

Bear Case

• Adjusted profit remains a narrow cushion. The August 6 Q2 release reported only $0.2 million of adjusted EBITDA. The same results showed a loss per share of $0.08 under generally accepted accounting principles, so adjusted profitability does not establish net profitability.
• New contracts require a ramp. The September presentation places treatment transition in months 1–4 and treatment optimization in months 9–12. Contract commencement therefore does not establish mature margins; a reduction of the FY2026 adjusted-EBITDA floor below $2 million would weaken the profitability case. September investor presentation.

Setup & Price Structure

The adjusted reference series records a $5.13 daily close on August 3, 2026, a three-month price increase of 25.7%, and a 14-day relative strength index of 32.0. These describe that dated observation; they do not establish September momentum. The company confirms that Nasdaq trading changed from TOI to STLN effective August 4, 2026. Company investor relations.

The averaging windows were not specified. Those observations cannot establish continuing outflows, retail crowding or present participation; the sample is too small to support that claim.

The $5.13 August 3 close remains the published structural threshold. It is a historical market reference, not verified support from a current moving average. No newer adjusted daily series is available in this record to establish whether the thesis has subsequently been invalidated.

Catalyst Calendar (next 30 days)

• 2026-10-01 — provisional contract commencement. The Wells Fargo moderator identified this start date for the new delegated contracts on September 8. Operational confirmation remains necessary; a disclosed postponement would fail the timing test. Conference transcript.

The September 8 conference has elapsed. No confirmed Q3 reporting date was established in the reviewed event record as of September 20, 2026. Company event page.

What Would Change Our Mind

Loss of the historical reference level would end the market thesis: a weekly close below $5.13 breaches the August 3, 2026 adjusted close. Separately, disclosed postponement of the Nevada or Oregon launches beyond Q4 2026, or FY2026 adjusted EBITDA below the $2 million floor published August 6, would break the operating case.

Confirmation requires reported contract commencement and FY2026 adjusted EBITDA meeting that floor before the price invalidation occurs. The available financial evidence supports medium conviction; the stale adjusted-price record limits assessment of the market structure.

Correlation Notes

This is a single-company contract-execution thesis. On September 8, CEO Daniel Virnich argued that Medicare Advantage reimbursement pressure increases payer demand for outsourced oncology management. That is management’s view, not a measured stock correlation; payer cancellations or adverse contract repricing would contradict the proposed benefit. Conference transcript.